FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2615709729> ?p ?o ?g. }

• W2615709729 abstract "Background: Immune checkpoint inhibitors have revolutionized the treatment of many malignancies with over a dozen new United States Food and Drug Administration (FDA) approvals in the past six years. Due to the combination of potent treatment success and potentially deadly adverse effects from immune checkpoint inhibitors, gathering prognostic and predictive information about FDA-indicated tumors is prudent. Method: PD-L1 expression is a poor prognostic factor and predictive of better responses from both PD-1 and PD-L1 inhibitors in a variety of tumor types including Renal Cell Carcinoma (RCC) and urothelial carcinoma. Each FDAapproved PD-1/PD-L1 drug is paired with a PD-L1 Immunohistochemistry (IHC) assay. The majority of PD-1/PDL1 inhibitor clinical trials use proprietary IHC antibodies with undefined validation data. Thus, there is need for improved knowledge and application of PD-1/PD-L1 IHC biomarkers. There is a wealth of recent publications using antibody clones to characterize tumor PD-1/PD-L1 expression profiles. Results: PD-1 is expressed on lymphocytes. PD-L1 is expressed on both tumor cells and immune cells. IHC staining appears in membranous fashion. A cutoff of at least 5% tumor cell PD-L1 staining for positivity has worked for most studies. Caution should be observed when employing tissue microarray techniques. Conclusion: RCC has been the most studied of the genitourinary malignancies for PD-L1 expression. The atezolizumab- approved IHC assay is unique in that only immune cell staining is quantified for the use of this assay in urothelial carcinoma. With familiarity of the current FDA guidelines, published medical literature, and general immunohistochemical considerations, the use of immune checkpoint biomarkers can continue to flourish. Keywords: Genitourinary tumors, bladder, kidney, immunotherapy, immune checkpoint blockade, PD-1/PD-L1 biomarkers." @default.
• W2615709729 created "2017-05-26" @default.
• W2615709729 creator A5003107448 @default.
• W2615709729 creator A5003455459 @default.
• W2615709729 creator A5011935671 @default.
• W2615709729 creator A5012233019 @default.
• W2615709729 creator A5028571081 @default.
• W2615709729 creator A5042026897 @default.
• W2615709729 creator A5058161742 @default.
• W2615709729 creator A5063795761 @default.
• W2615709729 creator A5071614462 @default.
• W2615709729 creator A5076510325 @default.
• W2615709729 creator A5082300423 @default.
• W2615709729 creator A5083997022 @default.
• W2615709729 creator A5091054206 @default.
• W2615709729 date "2017-10-16" @default.
• W2615709729 modified "2023-10-03" @default.
• W2615709729 title "Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives" @default.
• W2615709729 doi "https://doi.org/10.2174/1389200218666170518162500" @default.
• W2615709729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28524003" @default.
• W2615709729 hasPublicationYear "2017" @default.
• W2615709729 type Work @default.
• W2615709729 sameAs 2615709729 @default.
• W2615709729 citedByCount "23" @default.
• W2615709729 countsByYear W26157097292017 @default.
• W2615709729 countsByYear W26157097292018 @default.
• W2615709729 countsByYear W26157097292019 @default.
• W2615709729 countsByYear W26157097292020 @default.
• W2615709729 countsByYear W26157097292021 @default.
• W2615709729 countsByYear W26157097292022 @default.
• W2615709729 countsByYear W26157097292023 @default.
• W2615709729 crossrefType "journal-article" @default.
• W2615709729 hasAuthorship W2615709729A5003107448 @default.
• W2615709729 hasAuthorship W2615709729A5003455459 @default.
• W2615709729 hasAuthorship W2615709729A5011935671 @default.
• W2615709729 hasAuthorship W2615709729A5012233019 @default.
• W2615709729 hasAuthorship W2615709729A5028571081 @default.
• W2615709729 hasAuthorship W2615709729A5042026897 @default.
• W2615709729 hasAuthorship W2615709729A5058161742 @default.
• W2615709729 hasAuthorship W2615709729A5063795761 @default.
• W2615709729 hasAuthorship W2615709729A5071614462 @default.
• W2615709729 hasAuthorship W2615709729A5076510325 @default.
• W2615709729 hasAuthorship W2615709729A5082300423 @default.
• W2615709729 hasAuthorship W2615709729A5083997022 @default.
• W2615709729 hasAuthorship W2615709729A5091054206 @default.
• W2615709729 hasConcept C121608353 @default.
• W2615709729 hasConcept C126322002 @default.
• W2615709729 hasConcept C133507102 @default.
• W2615709729 hasConcept C143998085 @default.
• W2615709729 hasConcept C159654299 @default.
• W2615709729 hasConcept C193270364 @default.
• W2615709729 hasConcept C203014093 @default.
• W2615709729 hasConcept C204232928 @default.
• W2615709729 hasConcept C2775949291 @default.
• W2615709729 hasConcept C2777472916 @default.
• W2615709729 hasConcept C2777701055 @default.
• W2615709729 hasConcept C2780057760 @default.
• W2615709729 hasConcept C2780851360 @default.
• W2615709729 hasConcept C2781053074 @default.
• W2615709729 hasConcept C2781230642 @default.
• W2615709729 hasConcept C502942594 @default.
• W2615709729 hasConcept C71924100 @default.
• W2615709729 hasConcept C8891405 @default.
• W2615709729 hasConceptScore W2615709729C121608353 @default.
• W2615709729 hasConceptScore W2615709729C126322002 @default.
• W2615709729 hasConceptScore W2615709729C133507102 @default.
• W2615709729 hasConceptScore W2615709729C143998085 @default.
• W2615709729 hasConceptScore W2615709729C159654299 @default.
• W2615709729 hasConceptScore W2615709729C193270364 @default.
• W2615709729 hasConceptScore W2615709729C203014093 @default.
• W2615709729 hasConceptScore W2615709729C204232928 @default.
• W2615709729 hasConceptScore W2615709729C2775949291 @default.
• W2615709729 hasConceptScore W2615709729C2777472916 @default.
• W2615709729 hasConceptScore W2615709729C2777701055 @default.
• W2615709729 hasConceptScore W2615709729C2780057760 @default.
• W2615709729 hasConceptScore W2615709729C2780851360 @default.
• W2615709729 hasConceptScore W2615709729C2781053074 @default.
• W2615709729 hasConceptScore W2615709729C2781230642 @default.
• W2615709729 hasConceptScore W2615709729C502942594 @default.
• W2615709729 hasConceptScore W2615709729C71924100 @default.
• W2615709729 hasConceptScore W2615709729C8891405 @default.
• W2615709729 hasIssue "8" @default.
• W2615709729 hasLocation W26157097291 @default.
• W2615709729 hasLocation W26157097292 @default.
• W2615709729 hasOpenAccess W2615709729 @default.
• W2615709729 hasPrimaryLocation W26157097291 @default.
• W2615709729 hasRelatedWork W2336126017 @default.
• W2615709729 hasRelatedWork W2546607321 @default.
• W2615709729 hasRelatedWork W2615709729 @default.
• W2615709729 hasRelatedWork W2887937272 @default.
• W2615709729 hasRelatedWork W2899953288 @default.
• W2615709729 hasRelatedWork W3215044659 @default.
• W2615709729 hasRelatedWork W4206284710 @default.
• W2615709729 hasRelatedWork W4282940720 @default.
• W2615709729 hasRelatedWork W4292838584 @default.
• W2615709729 hasRelatedWork W4313373552 @default.
• W2615709729 hasVolume "18" @default.
• W2615709729 isParatext "false" @default.
• W2615709729 isRetracted "false" @default.
• W2615709729 magId "2615709729" @default.

• next